Takeda, Eisai Shares Hit Hard by Clogs in New-Drug Pipeline (Japan)
This article was originally published in PharmAsia News
Takeda Pharmaceutical and Eisai have both suffered severe stock plunges in the past few weeks despite positive earning reports. The drastic drops are largely the result of reported problems with two respective clinical trials. When Takeda announced on Oct. 29 that it would have to conduct more trials on its experimental hyperlipidemia treatment, its stock plummeted 900 billion yen. It has still not recovered, despite reported earnings that were up 12 percent. Eisai had the same problem when it reported promising profit margins for the first part of the year and still watched its stock drop 200 yen. Analysts say that tumble was caused by the delay of approval for its experimental Parkinson's disease treatment. Insiders explain that the seemingly inconsistent earnings and stock prices are due to investor fears about future patent expirations. Much of Takeda's and Eisai's success is built on the revenues of drugs whose patents will expire in 2010. If the companies do not obtain approval for their replacements in time, future earnings could go through the floor. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.